Alexander van Akkooi, MD, PhD, Netherlands Cancer Institute, Amsterdam, The Netherlands, gives an overview of a retrospective analysis which explored the real-world use of talimogene laherparepvec (T-VEC), an oncolytic virus, in unresectable melanoma. Dr van Akkooi outlines the findings of the study, comparing patterns of use of T-VEC in different countries. This interview took place during the 10th World Congress of Melanoma in conjunction with the 17th EADO Congress Interactive Virtual Meeting.